PRLD Prelude Therapeutics Incorporat
$4.59▼ -1.71%
Healthcare
Other
After hours
$4.60▲ +0.22%
Sep 11, 7:57 PM ET
Volume 520.3K
Avg Volume (10D) 483.1K
Key Metrics & Fundamentals
Market Cap
$366.30M
P/E Ratio
–
Div Yield
–%
52W Range
0.98 - 6.83
% vs 50 MA
-9.10%
% vs 200 MA
24.61%
RSI-14
36.7
MACD Histogram
-0.2000
Beta (1Y vs SPY)
1.97
Free Cash Flow
-$15.57M
Gross Rev
$5.70M
Gross Profit
$5.70M
EBITDA
-$15.10M
COGS
–
Operating Exp
$21.16M
Operating Income
-$15.45M
EBIT
-$15.45M
Pretax Income
-$13.92M
Net Income
-$13.92M
EPS (Diluted)
-0.14
Price & Volume History
Loading chart…
Recent News
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 11, 2026 11:01 AM
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial
MT Newswires · Sep 10, 2026 11:54 AM
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
GlobeNewswire · Sep 10, 2026 11:01 AM
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
Stocktwits · Aug 12, 2026 4:07 PM
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 11, 2026 11:00 AM
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
Zacks · Jul 31, 2026 1:55 PM
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Zacks · Jul 17, 2026 4:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See PRLD's money flow as a full page
Social Sentiment
No Reddit posts found for PRLD.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.